Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00000256
First received: September 20, 1999
Last updated: July 23, 2013
Last verified: July 2013

September 20, 1999
July 23, 2013
August 1995
November 1996   (final data collection date for primary outcome measure)
Choice of nitrous oxide vs placebo [ Time Frame: After 1.5 min of inhalation each of nitrous oxide then placebo ] [ Designated as safety issue: No ]
Subjects underwent 4 sessions consisting of 2 sample tests (inhaling placebo and inhaling varying doses of N2O), then choosing which inhalant they wanted for a choice test. The subject & the technician administering the inhalant were blinded. During each intervention and each session, subjects underwent psychomotor testing.
Mood
Complete list of historical versions of study NCT00000256 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
Reinforcing Effects of Brief Exposures to Nitrous Oxide

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine reinforcing effects of brief exposures to nitrous oxide in healthy volunteers.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
  • Opioid-Related Disorders
  • Substance-Related Disorders
  • Drug: 20% N2O
  • Drug: 40% N2O
  • Drug: 60% N2O
  • Drug: 80% N2O
  • Active Comparator: Placebo + 20% N2O
    0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
    Intervention: Drug: 20% N2O
  • Active Comparator: Placebo + 40% N2O
    0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
    Intervention: Drug: 40% N2O
  • Active Comparator: Placebo + 60% N2O
    0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
    Intervention: Drug: 60% N2O
  • Active Comparator: Placebo + 80% N2O
    0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
    Intervention: Drug: 80% N2O
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11
November 1996
November 1996   (final data collection date for primary outcome measure)

Please contact site for information.

Both
22 Years to 34 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000256
NIDA-08391-8, R01DA008391, R01-08391-8
Not Provided
University of Chicago
University of Chicago
National Institute on Drug Abuse (NIDA)
Principal Investigator: James Zacny, Ph.D. University of Chicago
University of Chicago
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP